Paradigm Biopharmaceuticals Ltd has released a press release.
Phase 3 Knee OA Trial Recruitment Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Drawdown of Tranche 2 under the Convertible Note Facility
- September 2025 Quarterly Activities Report & Appendix 4C
- Phase 3 Knee OA Trial Recruiting and Dosing in AUS & US
- Appendix 4E and 2025 Annual Report
- June 2025 Quarterly Activities Report & Appendix 4C
Later from Paradigm Biopharmaceuticals
- iPPS Phase 2 Biomarker Results Published in Leading Journal
- December 2025 Quarterly Activities Report & Appendix 4C
- Oral OA Animal Therapy Progresses via AVet Deal
- Published Canine Study Strengthens iPPS Phase 3 Rationale
- Drawdown of Tranche 3 under the Convertible Note Facility
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals